Vizsgálati helyszín

Kantonsspital Baden

Baden, SvájcMég nincs intézményhez kötve

33futó vizsgálat
14lezárt vizsgálat
0a helyszín által az elmúlt 60 napban megerősített vizsgálat
–nyelv nincs megadva

A helyszín még egy vizsgálatot sem erősített meg.

Futó vizsgálatok

Toboroz
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07149649· 2/3. fázis· Forrás
Toboroz
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
NCT07158489· 2. fázis· Forrás
Még nem toboroz
FAPI PET Imaging - An Exploratory Study
NCT07705074· 1/2. fázis· Forrás
Toboroz
Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
NCT07365423· 2. fázis· Forrás
Toboroz
LUCINAE Registry: Thoracic Cancers During Pregnancy
NCT07699861· Forrás
Toboroz
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
NCT07203053· 2. fázis· Forrás
Toboroz
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
NCT07020065· 2. fázis· Forrás
Toboroz
Pacing Advancements With Cost and Experience VALuation for Unified Patient-Led Clinical Evidence - the PACEVALUE Study
NCT07276139· Forrás
Toboroz
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080· 2/3. fázis· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· 3. fázis· Forrás
Toboroz
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· 3. fázis· Forrás
Toboroz
Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
NCT07617610· Forrás
Toboroz
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· 3. fázis· Forrás
Fut, nem toboroz
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323· 2. fázis· Forrás
Toboroz
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
NCT06284317· 3. fázis· Forrás
Toboroz
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06401980· 2. fázis· Forrás
Toboroz
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277· 3. fázis· Forrás
Fut, nem toboroz
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· 3. fázis· Forrás
Toboroz
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
NCT05718323· 2. fázis· Forrás
Toboroz
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254· 3. fázis· Forrás
Toboroz
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· 3. fázis· Forrás
Toboroz
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· 3. fázis· Forrás
Fut, nem toboroz
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
NCT04630730· 2. fázis· Forrás
Fut, nem toboroz
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416· 3. fázis· Forrás
Fut, nem toboroz
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· 3. fázis· Forrás
Fut, nem toboroz
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· 3. fázis· Forrás
Fut, nem toboroz
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318· 3. fázis· Forrás
Fut, nem toboroz
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
NCT04245514· 2. fázis· Forrás
Fut, nem toboroz
Enhancement of Stroke Rehabilitation With Levodopa
NCT03735901· 3. fázis· Forrás
Toboroz
The SwissPrEPared Study
NCT03893188· Forrás
Fut, nem toboroz
1st Line Durvalumab in PS 2 NSCLC Patients
NCT03620669· 2. fázis· Forrás
Fut, nem toboroz
Prostate Cancer Biobank
NCT04024475· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

Toboroz
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822· 1. fázis· Forrás
Lezárult
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· 3. fázis· Forrás
Lezárult
Comparing Two Different Approaches in Robotic-Assisted Renal Surgery
NCT05377632· Forrás
Leállították
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
NCT04832854· 2. fázis· Forrás
Lezárult
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
NCT04480372· 2. fázis· Forrás
Toboroz
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
NCT03819101· 3. fázis· Forrás
Lezárult
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
NCT03353831· 3. fázis· Forrás
Lezárult
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
NCT03297593· 2. fázis· Forrás
Leállították
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
NCT02933801· 2. fázis· Forrás
Lezárult
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
NCT02950051· 3. fázis· Forrás
Lezárult
Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
NCT02572843· 2. fázis· Forrás
Visszavonták
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
NCT02053311· 3. fázis· Forrás
Leállították
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
NCT02051218· 3. fázis· Forrás
Toboroz
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
NCT02102165· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 12.

Hibát jelzek